Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
2(66.7%)
N/A
1(33.3%)
3Total
Phase 3(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05234788Not ApplicableRecruiting

Renal Artery DenervatIon Using Radial accesS in Uncontrolled HyperTensioN

Role: lead

NCT01874470Phase 3Terminated

Renal Denervation by Allegro System in Patients With Resistant Hypertension

Role: lead

NCT02901704Phase 3Unknown

Renal Denervation by Iberis MultiElectrode Renal Denervation System in Patients With Primary Hypertension

Role: lead

All 3 trials loaded